Privia Health Group, Inc. (PRVA): Price and Financial Metrics


Privia Health Group, Inc. (PRVA): $22.92

0.12 (+0.53%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

PRVA POWR Grades

  • Growth is the dimension where PRVA ranks best; there it ranks ahead of 94.78% of US stocks.
  • PRVA's strongest trending metric is Quality; it's been moving up over the last 179 days.
  • PRVA's current lowest rank is in the Value metric (where it is better than 16.8% of US stocks).

PRVA Stock Summary

  • With a one year PEG ratio of 0.52, PRIVIA HEALTH GROUP INC is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than only 4.68% of US stocks.
  • The price/operating cash flow metric for PRIVIA HEALTH GROUP INC is higher than 98.98% of stocks in our set with a positive cash flow.
  • With a year-over-year growth in debt of -71.37%, PRIVIA HEALTH GROUP INC's debt growth rate surpasses merely 3.13% of about US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to PRIVIA HEALTH GROUP INC are CKX, LFST, SOPA, LTH, and DHIL.
  • Visit PRVA's SEC page to see the company's official filings. To visit the company's web site, go to www.priviahealth.com.

PRVA Valuation Summary

  • PRVA's price/sales ratio is 2.5; this is 4.17% higher than that of the median Technology stock.
  • PRVA's price/sales ratio has moved down 1.9 over the prior 19 months.

Below are key valuation metrics over time for PRVA.

Stock Date P/S P/B P/E EV/EBIT
PRVA 2022-11-14 2.5 6.7 -82.0 -74.2
PRVA 2022-11-11 2.4 6.5 -80.0 -72.2
PRVA 2022-11-10 2.6 6.9 -85.1 -77.3
PRVA 2022-11-09 2.4 6.4 -57.8 -55.9
PRVA 2022-11-08 2.7 7.1 -64.3 -62.9
PRVA 2022-11-07 2.7 7.1 -64.4 -63.0

PRVA Price Target

For more insight on analysts targets of PRVA, see our PRVA price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $46.00 Average Broker Recommendation 1.39 (Strong Buy)

PRVA Stock Price Chart Interactive Chart >

Price chart for PRVA

PRVA Price/Volume Stats

Current price $22.92 52-week high $44.64
Prev. close $22.80 52-week low $17.99
Day low $22.46 Volume 194,200
Day high $22.97 Avg. volume 839,995
50-day MA $31.64 Dividend yield N/A
200-day MA $29.95 Market Cap 2.62B

Privia Health Group, Inc. (PRVA) Company Bio


Privia Health Group, Inc. operates as a physician practice management and population health technology company in the United States. The company comprises regional medical groups, accountable care organizations, and specialty verticals. It offers technology and population health tools to enhance independent providers' workflows; management service organization that enables providers to reduce administrative work focus on their patients; single-TIN medical group that facilitates payer negotiation, clinical integration and alignment of financial incentives; physician-led accountable care organization, which engages patients, reduces inappropriate utilization, and enhances coordination and patient quality metrics to drive value-based care and transform the healthcare delivery system; and network for purchasers and payers. The company was founded in 2007 and is headquartered in Arlington, Virginia. Privia Health Group, Inc. operates as a subsidiary of Brighton Health Group Holdings, LLC.


PRVA Latest News Stream


Event/Time News Detail
Loading, please wait...

PRVA Latest Social Stream


Loading social stream, please wait...

View Full PRVA Social Stream

Latest PRVA News From Around the Web

Below are the latest news stories about PRIVIA HEALTH GROUP INC that investors may wish to consider to help them evaluate PRVA as an investment opportunity.

Privia Health Announces Pricing of Secondary Offering

ARLINGTON, Va., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (Nasdaq: PRVA, or “Privia Health” or the “Company”) announced the pricing of its previously announced underwritten public offering of 5,000,000 shares of common stock by certain selling stockholders at a public offering price of $23.50 per share. Such selling stockholders have granted the underwriters a 30-day option to purchase up to an additional 750,000 shares of the Company’s common stock. The Company will not receiv

Yahoo | November 17, 2022

Privia Health Announces Secondary Offering

ARLINGTON, Va., Nov. 15, 2022 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (Nasdaq: PRVA, or “Privia Health” or the “Company”) today announced the commencement of an underwritten public offering of 5,000,000 shares of common stock by certain selling stockholders. Such selling stockholders also intend to grant the underwriters a 30-day option to purchase up to an additional 750,000 shares of the Company’s common stock. The Company will not receive any of the proceeds from the sale of the shares

Yahoo | November 15, 2022

Privia Health Announces Change to its Board of Directors

ARLINGTON, Va., Nov. 15, 2022 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (Nasdaq: PRVA) today announced that Jeff Butler has resigned from the Company’s Board of Directors and as a member of the Compliance Committee of the Board, effective immediately. Mr. Butler’s resignation was not due to any disagreement with the Company on any matter relating to the Company’s operations, policies, or practices. Mr. Butler commented, “After 15 years since founding Privia Health, I am confident the Company

Yahoo | November 15, 2022

Privia Health Group Third Quarter 2022 Earnings: Beats Expectations

Privia Health Group ( NASDAQ:PRVA ) Third Quarter 2022 Results Key Financial Results Revenue: US$342.9m (up 36% from 3Q...

Yahoo | November 12, 2022

Analysts Offer Insights on Healthcare Companies: AstraZeneca (AZN), Ayr Wellness (OtherAYRWF) and Privia Health Group (PRVA)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on AstraZeneca (AZN – Research Report), Ayr Wellness (AYRWF – Research Report) and Privia Health Group (PRVA – Research Report). AstraZeneca (AZN) In a report released today, Andrew Berens from SVB Securities maintained a Buy rating on AstraZeneca, with a price target of $78.00. The company's shares closed last Thursday at $65.09. According to TipRanks.com, Berens is a 4-star analyst with an average return of 5.9% and a 57.1% success rate. Mayo covers the Healthcare sector, focusing on stocks such as Airsculpt Technologies, Inc., Alignment Healthcare, and Acadia Healthcare.

Catie Powers on TipRanks | November 11, 2022

Read More 'PRVA' Stories Here

PRVA Price Returns

1-mo -30.29%
3-mo -41.25%
6-mo N/A
1-year -3.33%
3-year N/A
5-year N/A
YTD -11.40%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6554 seconds.